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A B S T R A C TObjectives: This article proposes an integrated approach to the
development, validation, and evaluation of new risk prediction mod-
els illustrated with the Fungal Infection Risk Evaluation study, which
developed risk models to identify non-neutropenic, critically ill adult
patients at high risk of invasive fungal disease (IFD). Methods: Our
decision-analytical model compared alternative strategies for pre-
venting IFD at up to three clinical decision time points (critical care
admission, after 24 hours, and end of day 3), followed with antifungal
prophylaxis for those judged “high” risk versus “no formal risk
assessment.” We developed prognostic models to predict the risk of
IFD before critical care unit discharge, with data from 35,455 admis-
sions to 70 UK adult, critical care units, and validated the models
externally. The decision model was populated with positive predictive
values and negative predictive values from the best-ﬁtting risk
models. We projected lifetime cost-effectiveness and expected value
of partial perfect information for groups of parameters. Results: Thesee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.09.006
ue@lshtm.ac.uk.
ondence to: Z. Sadique, Department of Health Serv
istock Place, London WC1H 9SH, UK.risk prediction models performed well in internal and external
validation. Risk assessment and prophylaxis at the end of day 3 was
the most cost-effective strategy at the 2% and 1% risk threshold. Risk
assessment at each time point was the most cost-effective strategy at
a 0.5% risk threshold. Expected values of partial perfect information
were high for positive predictive values or negative predictive values
(£11 million–£13 million) and quality-adjusted life-years (£11 million).
Conclusions: It is cost-effective to formally assess the risk of IFD for
non-neutropenic, critically ill adult patients. This integrated approach
to developing and evaluating risk models is useful for informing
clinical practice and future research investment.
Keywords: cost-effectiveness analysis, critical care, invasive fungal
disease, risk prediction, value of information analysis.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Risk prediction models have great potential to support clinical
decisions and the development of clinical guidelines [1–5]. For
example, the decision to initiate statin therapy for the primary
prevention of cardiovascular disease may be informed by risk
equations from the Framingham study [6]. Treatment choice for
patients with breast cancer can be guided by estimates of the
long-term risk of cancer recurrence or death, for example, from
the Nottingham prognostic index [7]. Clinical decision making in
critical care units may be informed by estimates of the predicted
risk of death, based, for instance, on the acute physiology and
chronic health evaluation score [8,9]. In many circumstances,
however, it is unclear whether using risk prediction approaches
to initiate prevention and treatment strategies is cost-effective.Risk prediction models can be used in cost-effectiveness
analysis (CEA) to identify which patient subgroups are the most
cost-effective to receive a particular treatment or prevention
strategy [10–12]. For example, Grieve et al. [13] considered alter-
native Framingham equations to evaluate strategies for prevent-
ing cardiovascular disease, and Williams et al. [14] outlined the
use of a prognostic model to select patients with breast cancer for
systemic therapy. Longworth et al. [15] used published risk
prognostic models to evaluate the cost-effectiveness of liver
transplantation. None of these studies, however, evaluated
whether a strategy of formal risk assessment with a prognostic
model was cost-effective. Furthermore, previous CEAs have taken
a published risk prediction model and assumed that it is valid for
the decision context. The population characteristics in the deci-
sion context are often different from those of the population, onociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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liable extrapolations. To assess whether a risk prediction model is
valid in the speciﬁc decision context requires a careful assessment
of the statistical performance of the model for the relevant
population and time points. In particular, it is important to
consider whether the risk prediction model accurately predicts
events not only for the original population on which it was
developed (internal validation) but also for alternative populations
of prime interest for the decision problem (external validation). Of
greatest importance for decision making is the discrimination of
the risk model. If a risk model has perfect discrimination, then
there is a threshold risk that divides the patients into those who
will versus those who will not experience an event, leading to the
optimal treatment decision for every patient. In practice, perfect
discrimination will not be achieved, but improved discrimination
will lead to better decision making, reﬂected through the positive
predictive value (PPV) and the negative predictive value (NPV) of
the decision rule. In addition to developing risk models that are
accurate, it is important to evaluate the relative cost-effectiveness
of alternative risk prediction approaches.
There is growing appreciation of the need to evaluate risk
prediction models, but only a few studies have done this, and only
to a limited extent. Henriksson et al. [16] developed a risk prediction
model and assessed the cost-effectiveness of prognostic biomarkers
and risk scores to inform prioritization for coronary artery surgery.
Rapsomaniki et al. [17] evaluated the net beneﬁt from using a
prognostic model, illustrated in the context of the prevention of
cardiovascular disease. But none of the above studies has fully
assessed the uncertainty in the decision problem by assessing the
value of information to help support decision making. Value of
information analysis provides an important framework for deter-
mining the expected payoff of conducting further research to
resolve the parameter uncertainties that pervade the cost-
effectiveness estimates [18]. We propose an integrated approach
to considering risk prediction models in decision making. The
integrated approach considers developing, validating, and evaluat-
ing the cost-effectiveness of a risk prediction approach for the
relevant decision context, for example, according to the speciﬁc
population and time point of interest. This integrated approach also
requires that the ensuing decision uncertainty be fully recognized
by providing an assessment of the priorities for further research.
The integrated approach is illustrated with the Fungal Infec-
tion Risk Evaluation (FIRE) study, which developed prognostic
models to identify non-neutropenic, critically ill adult patients at
high risk of invasive fungal disease (IFD). For critically ill patients,
IFD is associated with increased morbidity, mortality, and cost
[19–21]. Randomized controlled trials have reported thatTable 1 – Alternative treatment strategies for non-neutro
Strategy D
On admission A
1 Do not assess risk Do
Risk assessment at a single time point
2 Assess risk, Prophylaxis if risk4PT Do
3 Do not assess risk Assess ris
4 Do not assess risk Do
Risk assessment at multiple time points
5 Assess risk, Prophylaxis if risk4PT Assess ris
6 Do not assess risk Assess ris
7 Assess risk, Prophylaxis if risk4PT Do
8 Assess risk, Prophylaxis if risk4PT Assess ris
PT, risk threshold.antifungal prophylaxis with either ﬂuconazole or ketoconazole
reduces the subsequent risk of IFD and mortality [22]. These
randomized controlled trials were conducted in high-risk
patients, and concerns about the costs of prophylaxis and
possible drug resistance have discouraged the widespread adop-
tion of antifungal prophylaxis. In the United Kingdom, risk
models are not routinely used to identify those non-neutropenic,
critically ill adult patients who are at high risk of IFD. Antifungal
prophylaxis is prescribed only on an ad-hoc basis for those
patients who, according to clinical judgment, are at very high
risk of IFD. In the FIRE study, only 1% of eligible patients received
systemic antifungal therapy at admission to the critical care unit
[23]. For the vast majority of patients admitted to critical care
units who do not currently receive antifungal prophylaxis, it is
unknown whether it is cost-effective to formally assess the risk
of IFD at different clinical decision time points, and to initiate
antifungal prophylaxis for those judged high risk.
The objective of this article was to illustrate an integrated
approach to the development, validation, and CEA of risk pre-
diction models through the FIRE case study. We use these risk
prediction models to report the relative cost-effectiveness of
alternative risk assessment and prophylaxis strategies for pre-
venting IFD and assess the relative value of further research.
The article proceeds as follows. The next section outlines the
decision, problem, and the CEA model, followed by a summary of
risk model development and validation. Following this are
sections on methods and results of CEA, scenario analysis, and
value of information (VOI) analysis. In the ﬁnal section, we
discuss the approach taken and suggest a research agenda.Overview of the Decision Problem and the CEA Model
The CEA aimed to assess the relative cost-effectiveness of
alternative strategies for assessing the risk of IFD and initiating
antifungal prophylaxis in non-neutropenic, adult patients admit-
ted to National Health Service critical care units in the United
Kingdom. The CEA reported cost-effectiveness over the patients’
lifetime and assessed costs from the National Health Service
perspective. The alternative prevention strategies comprised
“formal risk assessment” according to the predicted risk of IFD
at up to three clinical decision time points (from herein termed
“risk assessment”). These time points were at critical care unit
admission, after 24 hours, and at the end of the third calendar
day in the critical care unit (Table 1).
At any clinical decision time point, risk assessment was
considered only for those patients who were still in the criticalpenic, critically ill adult patients.
ecision node
t end of 24 h At end of day 3
not assess risk Do not assess risk
not assess risk Do not assess risk
k, Prophylaxis if risk4PT Do not assess risk
not assess risk Assess risk, Prophylaxis if risk4PT
k, Prophylaxis if risk4PT Do not assess risk
k, Prophylaxis if risk4PT Assess risk, Prophylaxis if risk4PT
not assess risk Assess risk, Prophylaxis if risk4PT
k, Prophylaxis if risk4PT Assess risk, Prophylaxis if risk4PT
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 1 1 – 1 1 2 2 1113care unit, not already receiving systemic antifungal therapy, and
without IFD before that time point. Patients whose predicted risk
was greater than a prespeciﬁed threshold (PT) were designated
“high risk.” The risk thresholds deﬁned a priori according to the
literature and expert opinion were 0.5%, 1%, 2%, 5%, and 10%. It
was assumed that antifungal prophylaxis was initiated for those
newly deﬁned as high risk at the particular clinical decision time
point. The prophylaxis treatment regimen was assumed to follow
current recommendations and was for 400 mg ﬂuconazole per
day for 10 days [22–25]. There is no speciﬁc guideline on the
duration of antifungal prophylaxis in critical care. A systematic
review [22] suggested that such prophylaxis is generally admin-
istered until discharge from critical care, but the duration varied
across studies. Our study assumed that prophylaxis was admin-
istered for 10 days, the average length of stay in critical care for
the study population. These strategies were contrasted to the
current practice of “no formal risk assessment or prophylaxis”
(Table 1) (from herein termed “no risk assessment”).
A decision analytical model (Fig. 1) was developed to evaluate
the alternative strategies for assessing the risk of IFD deﬁned in
Table 1. Alternative strategies at three clinical time points were
compared with current practice, leading to eight alternative
strategies under consideration. Each time point deﬁned a clinical
decision node, with two possibilities—either formal assessment
of the risk of IFD was not undertaken (no risk assessment) or risk
assessment was undertaken (risk assessment). If risk assessment
was not undertaken, patients at each time point i faced the risk of
either having IFD in the critical care unit (Ri) or not having IFD
(1  Ri). From the “no IFD” health state, patients faced a baseline
risk of all-cause death, and for patients predicted to develop IFD,
an excess risk of death was applied (see the section on CEA of
alternative risk assessment strategies).
Under the strategies in which risk assessment was under-
taken, the proportion of patients (Pi) whose predicted risk of
infection was higher than the risk threshold were judged high
risk and assumed to receive prophylaxis. For these patients, the
probability of developing IFD at any time during the stay on the
critical care unit was estimated from time point–speciﬁc positive
predictive value (PPVi) and the relative risk of IFD following
antifungal prophylaxis versus no prophylaxis [22]. The proportion
of patients (1  Pi) whose predicted risk of infection was lower
than the risk threshold were judged “low risk” and assumed not
to receive prophylaxis. For these patients, the probability of
developing IFD was estimated as 1 minus the NPV (1  NPVi).
The risk of death, conditional on the presence or absence of IFD,
was assumed the same whether or not patients received anti-
fungal prophylaxis.
The decision model required PPVs and NPVs for each clinical
decision time point because the patients who did not receive
antifungal prophylaxis may be reconsidered for risk assessment
and prophylaxis at subsequent clinical decision time points.Risk Model Development and Validation
Overview of the FIRE Study
The FIRE study collected data on 60,778 admissions to 96 adult,
general critical care units in the United Kingdom between July
2009 and March 2011 [23]. For the development of the risk models
and the CEA, the following exclusion criteria were applied: age
younger than 18 years, readmissions, neutropenia, active hema-
tological malignancy, admission following solid organ transplant,
receipt of systemic antifungal or IFD identiﬁed before the clinical
decision time point, and death or discharge from the critical care
unit before the clinical decision time point (for the second and
third time points).IFD was deﬁned as a blood culture or sample from a normally
sterile site positive for yeast or mould cells in a microbiological or
histopathological report. For risk model development and CEA,
IFD was restricted to infection with Candida species, which
accounts for 94% of the cases of IFD.
Model Development and Validation
Before evaluating the relative cost-effectiveness of risk prediction
models, it is important to validate the alternative models in the
appropriate decision context [26–29]. The model development
and validation are required to discriminate those patients who
will versus those who will not experience an event according to a
particular risk threshold, and so provide key parameters for the
decision model (e.g., the PPV and the NPV). In the FIRE study, we
performed internal validation, temporal validation, and external
validation. The alternative risk prediction models are initially
subject to internal validation. Here, the data set is split into two
parts, and cross-validation is undertaken, whereby the model is
developed on the ﬁrst portion (often called a development data
set) and predictive accuracy of the model is assessed on the
second portion of the data (known as the validation data set). In
temporal validation, the performance of the model is assessed on
subsequent patients from the same context, for example, the
same geographical location. The internal and temporal validation
of risk models is necessary but insufﬁcient; a true evaluation of
the generalizability of the risk prediction model requires evalua-
tion on data from external sources (external validation) [26,27].
In the FIRE study, risk models were developed to predict the
risk of IFD at the three clinical decision time points required for
the CEA. Here, we provide a brief summary; full details are
provided elsewhere [23,30]. The selection of risk factors for IFD
was informed by a systematic literature review [31]. The data set
was divided into the following development and validation
samples: 1) development sample—all admissions to a random
sample of participating critical care units in England, Wales, and
Northern Ireland, July 2009 to December 2010; 2) random valida-
tion sample—all admissions to the remaining units in England,
Wales, and Northern Ireland; 3) temporal validation sample—all
admissions to units in the development sample, January to March
2011; and 4) geographical validation sample—all admissions to
units in Scotland (Table 2). A sample size of 40,000 was selected
for model development on the basis of 20 events per variable
assuming 20 candidate predictors and an event rate of 1%. This
sample size provided 80% power to detect, as statistically signiﬁ-
cant (P o 0.05), a risk factor present in 10% of the population
associated with a 50% increase in the risk of IFD. A further 20,000
patients were included for external validation on the basis of a
split of development to validation data of two-thirds to one-third.
Logistic regression models with a backward stepwise approach
were used to model the risk of subsequently developing IFD. The
logistic regression method was chosen because this is the estab-
lished statistical technique for developing predictive models for
critical care [32]. There are concerns that stepwise logistic regres-
sion method can lead to biased and unstable results [33–35], and
so we used bootstrapping to guard against overﬁtting [26–28,36],
and in the CEA model used the estimates of the NPV and the PPV
from the validation rather than development data sets. Robust
standard errors from the Huber-White estimator [37,38] were used
to account for clustering of patients within critical care units. All
candidate variables identiﬁed from univariable analysis were
included in a multivariable model, and the model was progres-
sively simpliﬁed by using backwards stepwise selection. The ﬁnal
risk model at admission included the following variables: admis-
sion for presurgical preparation; surgery within up to 7 days before
admission (elective/scheduled with no unexpected complications,
elective/scheduled with unexpected complications, emergency/
Fig. 1 – Structure of the decision model comparing alternative strategies for assessing risk of IFD. IFD, invasive fungal disease;
NPV, negative predictive value; PPV, positive predictive value, RR, relative risk.
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Table 2 – Measures of risk prediction model performance in the development and validation samples.
Development sample
(n ¼ 35,455)
Validation sample
Original Optimism
adjusted
Random
validation
sample
(n ¼ 4,186)
Temporal
validation
sample
(n ¼ 9,866)
Geographical
validation
sample
(n ¼ 4,782)
Combined
validation
sample
(n ¼ 18,834)
At admission
c index* 0.705 0.688 0.721 0.650 0.640 0.655
Brier’s score† 0.0040 0.0041 0.0026 0.0043 0.0040 0.0038
24 h
c index 0.824 0.810 0.840 0.759 0.650 0.732
Brier’s score 0.0038 0.0038 0.0019 0.0042 0.0044 0.0037
End of day 3
c index 0.835 0.825 0.803 0.720 0.661 0.709
Brier’s score 0.0050 0.0050 0.0026 0.0049 0.0048 0.0043
 The c index is equivalent to the area under the receiver operating characteristic curve. A c index value of 0.5 indicates that the model is no
better at predicting the outcome than random chance, whereas a value of 1 suggests perfect discrimination.
† Brier’s score is the mean square error of the probability forecast over the validation sample and ranges between 0 (perfect predictions) and
0.25 (constant prediction of 0.5 for all patients).
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 1 1 – 1 1 2 2 1115urgent, no surgery); pancreatitis; number of catheters in central
veins; number of drains; enteral feeding tube; and number of
samples positive for fungal colonization. A full discussion of
variables included in risk prediction models at other clinical
decision time points is available elsewhere [23].
At each stage, the model was ﬁtted in the development
sample and the performance of the model was assessed. Model
discrimination was assessed with the c index [34], and the overall
ﬁt was assessed by using the Brier’s score [39]. Bootstrapping was
used to internally validate the ﬁnal model at each clinical
decision time point and to estimate optimism-adjusted measures
of discrimination and overall ﬁt [40].
The ﬁnal selected model at each clinical decision time point
was evaluated in the three external validation samples by using
the same performance measures as in the development sample.
Analyses were performed by using Stata Version 10.1 (StataCorp
LP, College Station, TX).
Results of Development and Validation of Risk Models
In total, 144 admissions (0.4%) in the development sample had
IFD. The risk model at admission had fair discrimination (c index
0.705). Discrimination improved at 24 hours (c index 0.824), and
this was maintained at the end of calendar day 3 (c index 0.835).
Despite the large sample size, the low incidence of IFD in the FIRE
study made robust statistical modeling difﬁcult. It is possible that
the risk models were overﬁtted, and this may contribute to the
drop in model performance when assessed in the validation
samples (Table 2).CEA of Alternative Risk Assessment Strategies
Estimation of Parameters for CEA Model
A decision analytical model was developed to consider current
clinical practice in the United Kingdom, which is “no formal risk
assessment and no prophylaxis,” versus seven comparator
strategies involving formal risk assessment and prophylaxis
at various time points. Because for this decision problem it was
not necessary to consider recurrent probabilities of events
over time, we used a simple decision tree rather than a broaderstructure such as a Markov model. The CEA model included
a hypothetical cohort of 1000 homogeneous cases with
characteristics deﬁned by the patients who met the FIRE study
inclusion criteria (see Table 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2013.09.006). The decision model
required the PPV and the NPV for each strategy and for each risk
threshold. The low incidence of IFD in the FIRE study meant that
at the higher prespeciﬁed risk thresholds of 5% and 10%, no
patients designated at high risk were predicted to have IFD, and
hence at these higher thresholds the PPV and NPV parameters
could not be estimated for the risk assessment strategies. Hence,
the risk thresholds considered in the CEA were 0.5%, 1%, and 2%.
To avoid concerns about overﬁtting from using the FIRE study
development data set, PPVs and NPVs were estimated from the
validation sample only (n ¼ 18,834). Table 3 presents PPVs and
NPVs for each strategy and risk threshold. The PPVs were low for
all strategies; even at the 2% risk threshold and with prophylaxis
at each clinical decision time point, the PPVs remained below 2%.
By contrast, the NPVs all exceeded 99%.
The baseline risk of infection (R1, R2, R3) and the baseline risk
of death were estimated for the three clinical decision time periods
from the combined FIRE study development and validation sam-
ples (n ¼ 54,289) (Table 4). For patients with IFD, the excess risk of
death was estimated from the combined FIRE data set. The relative
risk of IFD after prophylaxis was taken from the Cochrane system-
atic review by Playford et al. [22]. The systematic review reported
similar relative risks across different levels of baseline risk. Hence,
we applied the same relative risk of IFD after prophylaxis for all
clinical decision time points and all risk thresholds.
Costs, Life-Years, and Quality-Adjusted Life-Years
The cost of risk assessment assumed that, according to discus-
sion with three clinical experts in critical care, 10 minutes of
nursing time was required per patient, giving a cost of £8.67 [41].
Prophylaxis costs were calculated by assuming a standard regi-
men of ﬂuconazole 400 mg for 10 days with unit costs taken from
the British National Formulary [42]. The unit cost of prophylaxis
recognizes that according to the British National Formulary,
nonproprietary ﬂuconazole intravenous infusion was available
from September 2011. Lengths of stay in the critical care unit and
hospital were costed with corresponding unit cost per bed day
Table 4 – Input parameters for CEA model evaluating alternative risk assessment strategies for preventing IFD.
Parameter Time period Point
estimate
Distribution* Source
Baseline risk of IFD Within 24 h† 0.082% Beta (50; 60,728) Combined FIRE data
set‡24–48 h† 0.087% Beta (32; 36,911)
After 72 h† 0.449% Beta (102; 22,624)
Probability of death, no IFD Within 24 h 4.57% Beta (2,777; 57,999) Combined FIRE data set
24–48 h 5.82% Beta (2,151; 34,790)
After 72 h 8.78% Beta (3,057; 31,737)
Relative risk of death, IFD vs. no IFD During critical
care unit
2.14 lognormal (0.57 to 0.95) Systematic review [22]
Relative risk of IFD, prophylaxis vs. no
prophylaxis
During critical
care unit
0.46 lognormal (1.17 to 0.39) Systematic review [22]
Cost of course of prophylaxis (£) In critical care
unit
77.80 Gamma (0.98; 79.00) British National
Formulary [42]
Critical care unit LOS (d): no IFD In critical care
unit
10.16 Gamma (0.83; 12.18) Combined FIRE data set
Critical care unit LOS (d): IFD In critical care
unit
24.95 Gamma (1.82; 13.74) Combined FIRE data set
Hospital LOS (d): no IFD After critical care
unit
22.72 Gamma (0.57; 39.53) Combined FIRE data set
Hospital LOS (d): IFD After critical care
unit
36.60 Gamma (1.07; 34.22) Combined FIRE data set
Unit cost of critical care unit bed-day (£):
no IFD
1,085 Gamma (22.3; 48.63) Reference cost by HRG
[44]
Unit cost of critical care unit bed-day (£):
IFD
1,351 Gamma (31.06; 43.48) Reference cost by HRG
[44]
QALY§ 10.52 Gamma (127.96; 0.08) Published sources
[45–47]
CEA, cost-effectiveness analysis; CI, conﬁdence interval; FIRE, Fungal Infection Risk Evaluation; HRG, Health Resource Group; IFD, invasive
fungal disease; LOS, length of stay; QALY, quality-adjusted life-year.
 For beta distribution, the ﬁrst parameter refers to the number of events (alpha) and the second one refers to N  alpha. For gamma
distribution, the ﬁrst parameter refers to mean2/SE2 and the second parameters refers to SE2/mean, where SE represents standard error. For
lognormal distribution, the values in parentheses represent 95% CI of mean.
† These risks are calculated at speciﬁc time points. Overall, baseline risk of infection at any time during the study is 0.4%.
‡ Combined FIRE data set includes both development and validation data sets. See Table 2 for details.
§ QALY is calculated at mean age of patients (i.e., 60 y).
Table 3 – The PPV and the NPV according to strategy and risk threshold.
Strategy Clinical decision time point The PPV by risk threshold The NPV by risk threshold
0.5% 1.0% 2.0% 0.5% 1.0% 2.0%
1 No risk assessment – – – – – –
2 On admission 0.85% 1.94% 1.32% 99.95% 99.94% 99.92%
3 At end of 24 ho 0.88% 1.60% 1.35% 99.92% 99.93% 99.92%
4 At end of day 3 0.95% 1.21% 1.26% 99.79% 99.73% 99.65%
5 On admission 0.85% 1.94% 1.32% 99.95% 99.94% 99.92%
At end of 24 h 0.70% 1.31% 1.71% 99.92% 99.93% 99.92%
6 At end of 24 h 0.88% 1.60% 1.35% 99.92% 99.93% 99.92%
At end of day 3 0.98% 0.79% 1.62% 99.78% 99.72% 99.66%
7 On admission 0.85% 1.94% 1.32% 99.95% 99.94% 99.92%
At end of day 3 0.70% 0.99% 1.38% 99.78% 99.73% 99.64%
8 On admission 0.85% 1.94% 1.32% 99.95% 99.94% 99.92%
At end of 24 h 0.70% 1.31% 1.71% 99.92% 99.93% 99.92%
At end of day 3 0.57% 0.85% 1.70% 99.77% 99.73% 99.66%
Note: Data from Harrison D, Muskett H, Harvey S, et al. [23]. FIRE study full validation sample (n ¼ 18,805) (excludes 29 patients with missing
values).
FIRE, Fungal Infection Risk Evaluation; NPV, negative predictive value; PPV, positive predictive value.
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sources [43,44] (Table 4). All costs were adjusted to 2010–2011
price levels [41].
Life-years were calculated from the UK life tables by applying
all-cause mortality after hospital discharge from previous studies
and applied an excess mortality of 20% for up to 4 years [45–47].
The resultant life-years were combined with estimates of health-
related quality of life (HRQOL) for the UK general population [48]
to project lifetime quality-adjusted life-years (QALYs) for each
patient. To recognize that the HRQOL of critical care unit
survivors is lower than that of the general population, we
assumed that the HRQOL was 80% that of the age-gender–
matched general population [45]. Lifetime QALYs were calculated
for patients aged 60 years at admission, approximately the mean
age of patients included in the FIRE study. Future costs and
outcomes were discounted at the rate of 3.5% recommended by
the National Institute for Health and Care Excellence [4]. We used
Microsoft Excel 2007 for the cost-effectiveness analysis.Table 5 – Incremental cost (£), QALYs, and INBs (£) for eac
alternative risk thresholds.
Strategy Risk assessment thresholds and clinical decision
time points
1 No risk assessment
Risk threshold of 0.5% Time of risk assessment
2 On admission
3 At end of 24 h
4 At end of day 3
5 On admission and at end of
24 h
6 At end of 24 h and at end of
day 3
7 On admission and at end of
day 3
8 On admission, at end of 24 h,
and at end of day 3
Risk threshold of 1% Time of risk assessment
2 On admission
3 At end of 24 h
4 At end of day 3
5 On admission and at end of
24 h
6 At end of 24 h and at end of
day 3
7 On admission and at end of
day 3
8 On admission, at end of 24 h,
and at end of day 3
Risk threshold of 2% Time of risk assessment
2 On admission
3 At end of 24 h
4 At end of day 3
5 On admission and at end of
24 h
6 At end of 24 h and at end of
day 3
7 On admission and at end of
day 3
8 On admission, at end of 24 h,
and at end of day 3
INB, incremental net beneﬁt; QALY, quality-adjusted life-year.
 Incremental QALYs are rounded to four decimal places.
† Incremental costs and INBs are rounded to the nearest £. INBs are repImplementation
Incremental costs, incremental QALYs, and incremental net bene-
ﬁts (INBs), at a threshold of £20,000 per QALY, were calculated as
the differences in mean end points following each risk assessment
strategy versus the “no risk assessment.” A probabilistic sensitivity
analysis was conducted by resampling the input parameters 5000
times from recommended probability distributions [49,50]
(Table 4). Cost-effectiveness acceptability curves were calculated
according to the proportion of replications for which each strategy
was the most cost-effective, that is, had the maximum INBs across
all eight strategies, at different levels of willingness to pay for a
QALY gain (£0–£50,000 per QALY gained). The analyses were
repeated for the risk thresholds of 0.5%, 1%, and 2%.
Base-Case Analysis CEA Results
For the no risk assessment strategy, the mean total costs per
patient were £16,772, with mean lifetime QALYs of 8.63 (see Table 2h prophylaxis strategy versus no risk assessment for
Incremental
cost mean
Incremental
QALY* mean
INB† mean (95%
credible intervals)
– – –
10 0.0004 2 (60 to 65)
15 0.0000 16 (90 to 58)
7 0.0017 41 (81 to 162)
18 0.0005 7 (92 to 78)
6 0.0016 38 (89 to 165)
5 0.0020 46 (81 to 172)
4 0.0021 47 (100 to 194)
9 0.0001 8 (59 to 44)
12 0.0001 15 (79 to 50)
7 0.0013 33 (90 to 157)
19 0.0001 17 (103 to 69)
5 0.0014 32 (109 to 173)
3 0.0015 33 (105 to 171)
0 0.0016 32 (132 to 195)
8 0.0001 7 (22 to 8)
9 0.0000 8 (29 to 12)
4 0.0008 20 (23 to 64)
18 0.0001 16 (42 to 9)
2 0.0009 16 (32 to 64)
6 0.0008 10 (36 to 57)
10 0.0009 8 (47 to 63)
orted for the threshold of £20,000 per QALY.
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2013.09.006). Compared with the no risk assessment strategy, each
risk assessment strategy had positive but only small gains in
lifetime QALYs. The incremental costs of the risk assessment
strategies were negative for strategies with risk assessment at the
end of calendar day 3, whether at single or at multiple time points.
The INB at the risk threshold of 0.5% was highest when assessment
and prophylaxis were administered at all time points. For the risk
threshold of 1% to 2%, the highest INB was associated with risk
assessment and prophylaxis at the end of calendar day 3 (Table 5).
The most cost-effective risk assessment strategy differed according
to the threshold risk of IFD. At a 1% or 2% risk threshold, risk
assessment and prophylaxis at the end of calendar day 3 was the
most cost-effective strategy at the recommended cost-effectiveness
threshold of £20,000 per QALY gain. For the lower risk threshold (0.
5%), the strategy with the highest probability of being cost-effective
at £20,000 per QALY was to assess risk at each time point. At each
risk threshold, there was considerable uncertainty surrounding the
estimates of the relative cost-effectiveness of the alternative
strategies, and at the £20,000 per QALY threshold, the probability
that any particular strategy would be the most cost-effective did
not exceed 30% (Fig. 2).Scenario Analysis
The main assumptions made in the base-case analysis were
tested in the following scenario analyses:a. 5 or 20 minutes of nursing time to undertake the risk assess-
ment was considered.b. Reduction of 75% in the unit cost of ﬂuconazole. The rationale
for this cost reduction was evidence from the systematic review
that some randomized controlled trials have shown similar
effectiveness with 100 mg rather than 400 mg of ﬂuconazole
per day [22]. Another rationale for considering a 75% reduction in
the unit costs of ﬂuconazole is that even if the dose is main-
tained at 400 mg, local discounts in the range of 50% to 70%may
be available, and also ﬂuconazole may be provided in tablet form
once the patient is able to absorb the oral dose of ﬂuconazole.c. The duration of excess mortality was extended for up to 25
years [51].d. The HRQOL of critical care unit survivors was assumed to be
70% (rather than 80%) that of the general population.e. 5 or 14 days of prophylaxis duration as informed by system-
atic review [22] was considered.f. Best-case and worst-case scenario as deﬁned below were
considered: Best-case scenario: prophylaxis administered for
5 days, 10 minutes of nursing time, 75% reduction in the
prophylaxis unit cost, the HRQOL of survivors is 80% that of
the general population, and excess mortality for 4 years.
Worst-case scenario: prophylaxis administered for 14 days, 20
minutes of nursing time, full cost of prophylaxis, the HRQOL of
survivors is 70% that of the general population, and excess
mortality for 25 years.
The scenario analysis reported that the base-case results were
generally robust to the alternative assumptions considered (see
Table 3 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2013.09.006). Across risk thresholds and risk assessment
strategies, the scenarios that considered increased costs of assess
ment and prophylaxis (e.g., higher nursing time, higher duration of
prophylaxis) led to lower INB for the risk assessment strategies than
for the base case, assuming lower costs of assessment and prophy
laxis (e.g., lower nursing time, lower duration of prophylaxis) led to
higher INB. Excess mortality for 25 years and decrement in “qual
ity-of-life” weights shows a small effect on the INB. The generalconclusion that the strategies that included risk assessment at the
end of calendar day 3 were relatively cost-effective was robust to
the alternative “best-case” and “worst-case” scenarios considered.VOI Analysis
There is always the possibility that the preventative strategy that
appears the most cost-effective from current evidence would not
be the optimal approach if perfect information was available. The
expected costs of this decision uncertainty were quantiﬁed
according to the expected value of perfect information (EVPI)
[52]. The EVPI was calculated for the total population in the
United Kingdom that would be anticipated to beneﬁt from the
strategies considered. We assumed that the eligible population of
interest was 100,000 annual admissions to critical care units and
that the relevant life cycle for the technology was 5 years [23].
The results of the ensuing VOI analyses are conditional on model
structure and probability distributions for each parameter. The
EVPI sets an upper bound on the return of resolving all the
parameter uncertainties within the decision problem and
referred to as an upper bound on the value of further research.
At a threshold of £20,000 per QALY, the total EVPI estimates
ranged between £12 million (0.5% risk threshold) and £14 million
(1% risk threshold). Hence, across all parameters in the decision
model, the upper value of further research for the whole pop-
ulation of interest is high relative to the anticipated research
costs. To establish where further research might be best targeted,
we also reported the EVPI for parameters, or the expected value of
partial perfect information [18]. The groups of parameters con-
sidered were baseline probability of IFD, mortality with and
without IFD, PPV and NPV, relative risks of infection after
prophylaxis, morbidity costs, and lifetime QALYs.
Figure 3 reports the expected value of partial perfect informa-
tion estimates for each group of parameters by risk threshold.
The VOI for each group of parameters is similar across the risk
thresholds. The results also suggest that even after the FIRE
study, given the large population of interest for this decision
problem, further research to provide more precise estimates for
parameters such as the PPV or the NPV (£11 million–£13 million)
and QALYs (£11 million) is of high value.Discussion
This article presents an integrated approach to the development
of prognostic models for clinical decision making. The integrated
approach incorporates the development, validation, and evalua-
tion of alternative risk prediction models within the same study.
The approach is exempliﬁed by the FIRE study in which new risk
prediction models for IFD are developed, validated, and eval-
uated. The case study illustrates that it is necessary but insufﬁ-
cient for new risk models to show reasonable external validity in
random, temporal, and geographical validation samples. Before a
particular risk model can be recommended for use in clinical
practice, in this case to initiate antifungal prophylaxis, it is
important to assess the relative cost-effectiveness of alternative
risk prediction strategies. In the FIRE study, the incremental costs
of the risk assessment strategies compared with no risk assess-
ment strategy were positive for most of the strategies other than
a few strategies that were cost saving. The small cost differences
reﬂect the low unit costs of the prophylaxis, which was the
nonproprietary form of ﬂuconazole (400 mg per day). Each of the
risk assessment strategies had QALY gains compared with
current practice, but these were small and it could be argued
that these differences were less than the minimally important
difference in QALY gains [53]. The CEA that incorporated these
Fig. 2 – (A) Cost-effectiveness acceptability curves at risk threshold of 0.5%. (B) Cost-effectiveness acceptability curves at risk
threshold of 1%. (C) Cost-effectiveness acceptability curves at risk threshold of 2%.
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risk assessment and prophylaxis at all time points, and at the endof calendar day 3, was the strategy most likely to be cost-effective
when the risk threshold was 0.5% and 1% or 2%, respectively.
Fig. 3 – Population EVPPI at £20,000 per QALY, for alternative risk thresholds. EVPPI, expected value of partial perfect
information; NPV, negative predictive value; PPV, positive predictive value; QALY, quality-adjusted life-year.
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prediction approach may not be the most cost-effective. For
example, a risk prediction strategy at the end of 24 hours
provides the best discrimination (according to the c statistic
and Brier’s score from combined validation), but this strategy is
not the most cost-effective. An important aspect of the inte-
grated approach is VOI, as the FIRE study highlights that even
with a risk prediction model that performs reasonably well, the
decision uncertainty may be such that further research to
estimate parameters such as the NPV and the PPV with greater
precision can be worthwhile. Hence, an integrated approach to
the development and evaluation of such risk models can be
useful to inform both clinical decisions and future research
priorities.
This integrated approach to the development and evaluation
of risk prediction approaches within the same study has several
advantages over the more common approach whereby a risk
prediction model is developed in one study and used in a
subsequent CEA [11–15]. First, the integrated approach starts by
deﬁning the clinical decision problem and uses this to stipulate
which risk prediction model(s) is required. It can facilitate the
development of risk prediction models for speciﬁc treatment
modalities or patient subgroups, relevant to the decision prob-
lem. Second, the article follows guidelines for the development
and validation of a risk model [34,36] and extends previous work
[16,17] in this area by adopting a more extensive validation of the
risk prediction model than that routinely undertaken and by
evaluating the accompanying decision uncertainty.
This article extends previous uses of risk prediction models in
CEA [9,11–17], and while this integrated approach has been con-
sidered in the speciﬁc example of the FIRE study, it can be applied
more generally. Possible examples include evaluating strategies for
preventing emergency admissions in high-risk patients [1], initiat-
ing high-cost treatments for patients with hepatitis C infection,
initiating herceptin treatment in subgroups of patients with breast
cancer [54–56], and targeting treatment for severe sepsis inintensive care [46,57]. While in each of these areas prognostic
models exist, it would be useful to assess whether the additional
costs of categorizing patients for receiving treatment according to
new prognostic markers (such as IL28 for hepatitis C) are
worthwhile.
This study has some limitations. First, the approach is illustrated
and no consideration is given to the prevention of onward trans-
mission. In the FIRE study, when the risk predictionmodels included
an additional variable to indicate the presence of another patient
with IFD in the critical care unit at the same time, this did not
improve model performance, which suggests that onward trans-
mission was not amajor factor. Second, the CEA results do not apply
to the small minority of patients in critical care units currently
prescribed antifungal prophylaxis according to clinical judgment (1%
of eligible admissions in the FIRE study). Even when patients who
received antifungal prophylaxis were included in the study, the
baseline risk of IFD remained low (o0.5%). Third, the integrated
approach allowed the development and validation of risk prediction
models according to each clinical decision time point, but validation
was performed only at each single time point whereas the decision
problem included risk assessment at multiple time points.
Last, the decision analytical model ignored any impact of the
increased use of prophylaxis on antifungal resistance. Including the
effects of resistance on the costs and health outcomes of future
patients would reduce the relative cost-effectiveness of the risk
assessment strategies compared with current practice. In partic-
ular, while at the lower risk threshold (0.5%), the most cost-effective
strategy was to assess risk, and to provide prophylaxis for those
patients whose predicted risk exceeded the threshold, this would
require around one-third of patients to receive antifungal prophy-
laxis. Providing antifungal prophylaxis to a high proportion of
critically ill patients raises concerns that future patients may then
be resistant to ﬂuconazole. The possible consequences of resistance
to antifungal prophylaxis could include increased lengths of stay
in critical care units and in hospitals, the additional diagnostic
tests, and treatment costs for patients infected with a resistant
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antifungal agents unusable—either because they are no longer
effective or because of the fear of resistance. This may then make
next-generation antifungals necessary, which has implication on
both time and cost of developing next-generation antifungals.
Studies to date have not fully assessed the cost of resistance to
antifungal prophylaxis. In a related context, Smith and Coast [59]
highlighted that published studies underestimated the true costs of
antibacterial resistance. Further research is required to consider the
full costs of antifungal prophylaxis in terms of the additional
burden to future patients whose treatment with antifungal agents
becomes inappropriate due to increased resistance [60]. Incorporat-
ing these effects of resistance in decision analytic modeling is
challenging because it requires estimates of additional parameters,
such as the resistance rate, the ensuing effect on morbidity and
mortality, and a broader model structure, to consider future
populations who may be affected by increased resistance.
The integrated approach proposed offers some interesting
avenues for further research. The development of risk prediction
methods could be extended to other techniques proposed in the
methodological literature such as neural networks, support
vector machines, and random forests [61–66]. While there is
some evidence from simulation studies that these approaches
can improve prediction, they are less transparent [67]. More
importantly, such approaches should be subjected to the same
scrutiny as the integrated approach presented here.
In conclusion, this article illustrates an integrated approach to
developing and evaluating risk models within the same study.
This approach can be applied more generally to help decision
makers appropriately target treatment and prevention strategies.Acknowledgments
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